Investigational drug · Phase 2
SHR-2173
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Generalized Myasthenia Gravis, Active Lupus Nephritis, Primary IgA Nephropathy.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
9
Any phase or sponsor naming "SHR-2173"
First trial start
2025
Nov 22, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR-2173", any sponsor or status.
Conditions studied
As listed on its trial records.
- Generalized Myasthenia Gravis
- Active Lupus Nephritis
- Primary IgA Nephropathy
- Primary Membranous Nephropathy
- Systemic Lupus Erythematosus
Approved drugs for the same conditions: Myasthenia gravis · Lupus (SLE) · IgA nephropathy · Neurology · Immunology and inflammation · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR-2173" as an intervention, largest first.
- A Study of SHR-2173 in Participants With Systemic Lupus ErythematosusPivotal-lookingRecruiting
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07299422 · 248 participants (planned) · Start Apr 3, 2026 · Primary completion Mar 2028
Drug: SHR-2173 Injection; SHR-2173 Injection Placebo · For: Systemic Lupus Erythematosus
Sites: Beijing, China; Shanghai, China
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07354932 · 84 participants (planned) · Start Mar 9, 2026 · Primary completion Apr 2027
Drug: SHR-2173 injection; SHR-2173 injection and 2 more · For: Primary IgA Nephropathy
Sites: Guangzhou, China; Shanghai, China
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07289763 · 75 participants (planned) · Start Dec 31, 2025 · Primary completion Aug 2027
Drug: SHR-2173 injection; SHR-2173 injection and 1 more · For: Primary Membranous Nephropathy
Sites: Nanjing, China
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07622342 · 60 participants (planned) · Start Aug 28, 2026 · Primary completion Sep 2027
Drug: SHR-2173 injection; SHR-2173 injection and 1 more · For: Generalized Myasthenia Gravis
Sites: Changsha, China; Shanghai, China
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07229742 · 51 participants (planned) · Start Nov 22, 2025 · Primary completion Jun 2027
Drug: SHR-2173 Injection; SHR-2173 Injection Blank Preparation · For: Active Lupus Nephritis
Sites: Nanjing, China
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT06995001 · 35 participants · Start Apr 28, 2024 · Primary completion Nov 28, 2024
Drug: SHR-2173; SHR-2173 ;Placebo and 3 more · For: Healthy Volunteers
Sites: Haikou, China
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT06955598 · 30 participants · Start Nov 24, 2024 · Primary completion Nov 10, 2025
Drug: SHR-2173 · For: Systemic Lupus Erythematosus
Sites: Shanghai, China
Atridia Pty Ltd.Industry
NCT07390747 · 18 participants · Start Mar 6, 2026 · Primary completion May 22, 2026
Drug: SHR-2173 Injection/SHR-2173 placebo · For: Immunology
Sites: Melbourne, Australia
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07206758 · 10 participants (planned) · Start Nov 12, 2025 · Primary completion Jun 2026
Drug: SHR-2173 Injection · For: Immune Thrombocytopenia
Sites: Wuhan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Generalized Myasthenia Gravis
- FelzartamabPhase 38 trials
Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease
- TelitaciceptRC18, RC18-LPhase 38 trials
RemeGen Co., Ltd. · CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease
- IMVT-1402Phase 37 trials
Immunovant Sciences GmbH · Graves' Disease, Rheumatoid Arthritis, Subacute Cutaneous Lupus Erythematosus
- CemdisiranALN-CC5Phase 35 trials
Regeneron · Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, Age-related Macular Degeneration (AMD)
- B007Phase 33 trials
Shanghai Jiaolian Drug Research and Development Co., Ltd · Pemphigus, Primary Membranous Nephropathy, Generalized Myasthenia Gravis
- KYV-101Phase 32 trials
Kyverna Therapeutics · Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.